MolecuLight is excited to announce their collaboration with SerenaGroup, Inc. to conduct their biggest multi-center clinical trial to date, in the USA. The trial is an evaluation of the MolecuLight i:X as an adjunctive fluorescence imaging tool to clinical signs and symptoms for the identification of bacteria-containing wounds.
This is a non-randomized evaluation for which 160 adult patients will be imaged at outpatient wound care clinics who present with a wound of unknown infection diagnostic status and are receiving standard treatment. The MolecuLight i:X Imaging Device will be used as an adjunctive tool in the assessment of the wound and may be used to guide the targeted sampling of a wound (using a conventional punch biopsy method).
